Cost Effectiveness and Resource Allocation

Table 1 Transition probabilities matrix

From: Is Aducanumab treatment developed to prevent progression of Alzheimer's disease cost-effective in Turkey?

	Mild AD	Moderate AD	Severe AD	Death
Mild AD	0.774	0.158	0.013	0.055
Moderate AD	0.070	0.501	0.214	0.215
Severe AD	0.001	0.027	0.492	0.480
Death	0.000	0.000	0.000	1.000

Reference: [32]

Back to article page

ISSN: 1478-7547

Contact us

General enquiries: journalsubmissions@springernature.com